Source link : https://newshealth.biz/health-news/novel-complement-targeting-agent-shows-benefit-in-myasthenia-gravis/
(MedPage Today) — SAN FRANCISCO — The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The trial tested two doses of… Source link : https://www.medpagetoday.com/meetingcoverage/aanem/118269 Author : Publish date : 2025-11-01 20:00:00 Copyright for syndicated content belongs to the linked Source.
The post Novel Complement-Targeting Agent Shows Benefit in Myasthenia Gravis first appeared on News Health.
—-
Author : News Health
Publish date : 2025-11-01 20:00:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8